ASLN - ASLAN Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

30.49M

Cash

40.94M

Avg Qtr Burn

-14.71M

Short % of Float

1.91%

Insider Ownership

0.08%

Institutional Own.

39.13%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Eblasakimab (ASLAN004) (IL-13Ra1 inhibitor) Details Atopic dermatitis	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EblasaKimab Details Atopic dermatitis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Farudodstat (ASLAN003) (DHODH inhibitor) Details Autoimmune disease, Alopecia areata	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.